U.S. markets closed

Allena Pharmaceuticals, Inc. (ALNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1500+0.0400 (+3.60%)
At close: 4:00PM EDT
Sign in to post a message.
  • V
    ValuFin
    Massively undervalued for the populations it serves. That includes all enteric hyperoxaluria and a large chunk of hyperuricemia. A DCF while accounting for even a small chance of trials success puts it at $3.4.
    Bullish
  • R
    Ralloszek
    Phase 1 multiple ascending dose study is expected to initiate in the second quarter of 2021, with initial results expected in the third quarter. Additionally, pending feedback from the FDA, a Phase 2a program in patients with hyperuricemia is planned for the second half of 2021, with initial efficacy data expected during the fourth quarter.
    Bullish
  • t
    thomas
    Some news regarding patients being dosed for 346 would be nice to stop some of the bleeding
  • Z
    Zev
    Easy buy right now. This is either the bottom or we have another 10-20% max downside while we have 100% upside conservatively within 12 months.
  • J
    John
    About time to pop
  • P
    Pined
    “Galectin Therapeutics jumps 16%, world-renowned Dr. Ben Carson joins as special consultant”. This is how to boost your sp!
  • R
    Ralloszek
    bought 40k shares at 1.12
    Bullish
  • Z
    Zev
    Seems like we bottomed last week. Looking forward to some great upward movement in the coming weeks. The upside here is enormous to anyone willing to be patient.
    Bullish
  • P
    Pined
    Another 1M shares given as an “inducement for employment”?! When do shareholders get their inducements??
  • Z
    Zev
    Congrats to everyone that bought last week!
    Bullish
  • V
    ValuFin
    They already had a previous ATM with a different underwriter. So the ATM filed now is only an exchange of contracts = it’s a no-news event.
    Bullish
  • T
    Twitr
    In case you missed it a few weeks ago:

    "I was enthusiastic when I saw the data...I’m ready to write a prescription for it.” ~David S. Goldfarb, MD, NYU

    “Based on these data, reloxaliaseis definitely better than anything we have in clinical practice today.” ~Orson Moe, MD, University of Texas Southwestern
    Bullish
  • T
    Twitr
    Every time this stock starts to pop a little, someone rushes in to sell off and lower the price...
  • V
    VK
    I am out. Went in @2.05, can't ride it anymore. buh bye alna, gl every1
  • C
    Christopher
    FYI Cash flow will run out this year. Will need to issue 40 million more shares before 2022.
  • H
    H
    No matter how good a company is, when they are aligning to do an offering to raise cash because they are running out of cash, it's always bad news for shareholders. Some on this board saw this coming and bailed early.
  • Z
    Zev
    Very good sign that even on a red day stock is green. Stock is showing signs that it has bottomed!
    Bullish
  • A
    Anonymous
    Allena Pharmaceuticals Files Prospectus Supplement Related To Issuance, Sale Of Up To $50M Of Common Stock
    Bearish
  • J
    JOE
    BUY every share you can afford!
  • T
    Twitr
    From today's presentation:

    Enthusiastic KOL Feedback on URIROX-1 Results

    "I was enthusiastic when I saw the data...I’m ready to write a prescription for it.” ~David S. Goldfarb, MD, NYU

    “Based on these data, reloxaliaseis definitely better than anything we have in clinical practice today.” ~Orson Moe, MD, University of Texas Southwestern

    http://ir.allenapharma.com/static-files/8908e1e1-784b-4cd7-96ae-3f18a9945b15
    Bullish